International Cancer Genome Consortium
French Cohort
Powered by SNPnexus
Overview
Help
Sex
Survival Status
Age at Diagnosis
Loading...
Cancer Genome Interpreter (CGI) help
| Gene | Protein Alteration | Alteration Match | Drug | Effect | Tumour | Evidence |
|---|---|---|---|---|---|---|
| PDGFRA | PDGFRA MUT* (intron_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| RAF1 | RAF1 MUT* (intron_variant) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (intron_variant) | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (intron_variant) | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ESR1 | ESR1 MUT* (intron_variant) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| EGFR | EGFR MUT* (intron_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (intron_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| JAK2 | JAK2 MUT* (intron_variant) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| MET | MET MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| ERBB4 | ERBB4 MUT* (intron_variant) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (intron_variant) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (intron_variant) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (intron_variant) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (intron_variant) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (intron_variant) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (intron_variant) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (intron_variant) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (intron_variant) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| NTRK3 | NTRK3 MUT* (intron_variant) | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (intron_variant) | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (intron_variant) | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (intron_variant) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| PML | PML MUT* (intron_variant) | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | PML MUT* (intron_variant) | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | PML MUT* (intron_variant) | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| AKT3 | AKT3 MUT* (intron_variant) | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| JAK2 | JAK2 MUT* (intron_variant), JAK2 MUT* (E846Q) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (intron_variant) | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (intron_variant) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NRG1 | NRG1 MUT* (intron_variant) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | NRG1 MUT* (intron_variant) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| EGFR | EGFR MUT* (3-UTRSNV), EGFR MUT* (intron_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (3-UTRSNV), EGFR MUT* (intron_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ROS1 | ROS1 MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (intron_variant) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (intron_variant) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| BRAF | BRAF MUT* (intron_variant) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (intron_variant) | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (intron_variant) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | BRAF MUT* (intron_variant) | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (L2150L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (L2150L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (L2150L) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (L2150L) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (L2150L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (intron_variant) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (intron_variant) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (intron_variant) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (intron_variant) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (intron_variant) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (intron_variant) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (intron_variant) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (intron_variant) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (intron_variant) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| TP53 | TP53 MUT (R273S) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R273S) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R273S) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R273S) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R273S) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R273S) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R273S) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273S) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273S) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R273S) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R273S) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273S) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273S) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R273S) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273S) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | PIK3CA MUT (N345K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (N345K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| FGFR2 | FGFR2 MUT* (intron_variant) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT* (intron_variant) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| NTRK1 | NTRK1 MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | NTRK1 MUT* (intron_variant) | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | NTRK1 MUT* (intron_variant) | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | NTRK1 MUT* (intron_variant) | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| TP53 | TP53 MUT (D281G) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (D281G) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (D281G) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (D281G) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (D281G) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (D281G) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (D281G) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D281G) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D281G) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (D281G) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (D281G) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D281G) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (D281G) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (D281G) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (D281G) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E68*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E68*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E68*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E68*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E68*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E68*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E68*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E68*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E68*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E68*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E68*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E68*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E68*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E68*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E68*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CDH1 | CDH1 MUT (Q23*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| ESR1 | ESR1 MUT* (3-UTRSNV), ESR1 MUT* (intron_variant) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545A) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E545A) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (Y220*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y220*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y220*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y220*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y220*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y220*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y220*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y220*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y220*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y220*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y220*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y220*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EGFR | EGFR MUT* (3-UTRSNV) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (3-UTRSNV) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (H1047R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ROS1 | ROS1 MUT* (K2111R) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (K2111R) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (K2111R) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (K2111R) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (K2111R) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| ABL1 | ABL1 MUT* (E849Q) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | ABL1 MUT* (E849Q) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (E849Q) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | ABL1 MUT* (E849Q) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (E849Q) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | ABL1 MUT* (E849Q) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| TP53 | TP53 MUT (R248W) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R248W) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R248W) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R248W) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R248W) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R248W) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R248W) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R248W) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| JAK2 | JAK2 MUT* (intron_variant), JAK2 MUT* (E66Q) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| RAF1 | RAF1 MUT* (R143L) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (R143L) | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (R143L) | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| NTRK1 | NTRK1 MUT* (V393V) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | NTRK1 MUT* (V393V) | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | NTRK1 MUT* (V393V) | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | NTRK1 MUT* (V393V) | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| BRD4 | BRD4 MUT* (intron_variant) | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| ERBB4 | ERBB4 MUT* (intron_variant), ERBB4 MUT* (E742K) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | TP53 MUT (H178D) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (H178D) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (H178D) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (H178D) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (H178D) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (H178D) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (H178D) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H178D) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H178D) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (H178D) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (H178D) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H178D) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H178D) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (H178D) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H178D) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ESR1 | ESR1 MUT* (intron_variant), ESR1 MUT* (A65V) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| PDGFB | PDGFB MUT* (intron_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | DFS | FDA guidelines |
| TMPRSS2 | TMPRSS2 MUT* (intron_variant) | Different Alteration | DNA-PKc inhibitor | Responsive | PRAD | Pre-clinical |
| TMPRSS2 | TMPRSS2 MUT* (intron_variant) | Different Alteration | PARP inhibitor | Responsive | PRAD | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R175H) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R175H) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R273H) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R273H) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R273H) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R273H) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R273H) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R273H) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R273H) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273H) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273H) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R273H) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R273H) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273H) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273H) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R273H) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273H) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATR | ATR MUT (W1196*) | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATR | ATR MUT (W1196*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | CANCER, OV | Pre-clinical |
| ATR | ATR MUT (W1196*) | Different Alteration | Olaparib (PARP inhibitor) | Responsive | OV, CANCER | Pre-clinical |
| PIK3CA | PIK3CA MUT (P366R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (P366R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PLCG2 | PLCG2 MUT (splice_acceptor_variant) | Different Mutation | Ibrutinib (BTK inhibitor) | Resistant | CLL | Early trials |
| ROS1 | ROS1 MUT* (V1418I), ROS1 MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (V1418I), ROS1 MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (V1418I), ROS1 MUT* (intron_variant) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (V1418I), ROS1 MUT* (intron_variant) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (V1418I), ROS1 MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| TP53 | TP53 MUT (P278L) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (P278L) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (P278L) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (P278L) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (P278L) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (P278L) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (P278L) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278L) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278L) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (P278L) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (P278L) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278L) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (P278L) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (P278L) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (P278L) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | PIK3CA MUT (E545K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E545K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (Y205H) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y205H) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y205H) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y205H) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y205H) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y205H) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y205H) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y205H) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y205H) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y205H) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y205H) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y205H) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y205H) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y205H) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y205H) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB4 | ERBB4 MUT* (I404V) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (5-UTRSNV) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| BRCA2 | BRCA2 MUT (S1013*) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Case report |
| BRCA2 | BRCA2 MUT (S1013*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA2 | BRCA2 MUT (S1013*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA2 | BRCA2 MUT (S1013*) | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA2 | BRCA2 MUT (S1013*) | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA2 | BRCA2 MUT (S1013*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | PA | Case report |
| BRCA2 | BRCA2 MUT (S1013*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA2 | BRCA2 MUT (S1013*) | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA2 | BRCA2 MUT (S1013*) | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| BRCA2 | BRCA2 MUT (S1013*) | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA2 | BRCA2 MUT (S1013*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA2 | BRCA2 MUT (S1013*) | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA2 | BRCA2 MUT (S1013*) | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| BRCA2 | BRCA2 MUT (S1013*) | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| ABL1 | ABL1 MUT* (intron_variant) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | ABL1 MUT* (intron_variant) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (intron_variant) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | ABL1 MUT* (intron_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (intron_variant) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | ABL1 MUT* (intron_variant) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| JAK2 | JAK2 MUT* (W737C), JAK2 MUT* (intron_variant) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| CRLF2 | CRLF2 MUT* (intron_variant) | Different Alteration | MTOR inhibitor | Responsive | ALL | Pre-clinical |
| CRLF2 | CRLF2 MUT* (intron_variant) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| TP53 | TP53 MUT (K132R) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (K132R) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (K132R) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (K132R) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (K132R) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (K132R) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (K132R) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (K132R) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (K132R) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (K132R) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (K132R) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (K132R) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (K132R) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (K132R) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (K132R) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RET | RET MUT* (intron_variant), RET MUT* (3-UTRSNV) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (intron_variant), RET MUT* (3-UTRSNV) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (intron_variant), RET MUT* (3-UTRSNV) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (intron_variant), RET MUT* (3-UTRSNV) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (intron_variant), RET MUT* (3-UTRSNV) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (intron_variant), RET MUT* (3-UTRSNV) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (intron_variant), RET MUT* (3-UTRSNV) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (intron_variant), RET MUT* (3-UTRSNV) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (intron_variant), RET MUT* (3-UTRSNV) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| RB1 | RB1 MUT (splice_donor_variant) | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | RB1 MUT (splice_donor_variant) | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (splice_donor_variant) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (splice_donor_variant) | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (splice_donor_variant) | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (splice_donor_variant) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (splice_donor_variant) | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| VHL | VHL MUT (P95L) | Complete Match | VEGFR inhibitor | Responsive | R | Pre-clinical |
| ERBB4 | ERBB4 MUT* (Y123N) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (M237I) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (M237I) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (M237I) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (M237I) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (M237I) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (M237I) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (M237I) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | PIK3CA MUT (C420R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (C420R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (V216M) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (V216M) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (V216M) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (V216M) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (V216M) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (V216M) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (V216M) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V216M) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V216M) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (V216M) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (V216M) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V216M) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V216M) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (V216M) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V216M) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | PIK3CA MUT (E545D), PIK3CA MUT (Q546K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E545D), PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E545D), PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E545D), PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545D), PIK3CA MUT (Q546K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545D), PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545D), PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E545D), PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545D), PIK3CA MUT (Q546K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545D), PIK3CA MUT (Q546K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E545D), PIK3CA MUT (Q546K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545D), PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E545D), PIK3CA MUT (Q546K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E545D), PIK3CA MUT (Q546K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (S241F) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (S241F) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (S241F) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (S241F) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (S241F) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (S241F) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (S241F) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S241F) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S241F) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (S241F) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (S241F) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S241F) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (S241F) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (S241F) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (S241F) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH2 | NOTCH2 MUT (Q134*) | Different Mutation | Mk-0752 (Gamma secretase inhibitor) | Responsive | ALL, AML, BRCA | Early trials |
| NOTCH2 | NOTCH2 MUT (Q134*) | Different Mutation | OMP-59R5 (NOTCH2 inhibitor) | Responsive | SOLID | Early trials |
| NOTCH2 | NOTCH2 MUT (Q134*) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Complete Match | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| BRAF | BRAF MUT* (intron_variant), BRAF MUT* (3-UTRSNV) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (intron_variant), BRAF MUT* (3-UTRSNV) | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (intron_variant), BRAF MUT* (3-UTRSNV) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | BRAF MUT* (intron_variant), BRAF MUT* (3-UTRSNV) | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | PI3K pathway inhibitor;MEK inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | ERBB3 mAb inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (V104L) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| TP53 | TP53 MUT (G266V) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (G266V) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (G266V) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (G266V) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (G266V) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (G266V) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (G266V) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G266V) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G266V) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (G266V) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (G266V) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G266V) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G266V) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (G266V) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G266V) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (D281H) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (D281H) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (D281H) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (D281H) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (D281H) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (D281H) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (D281H) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D281H) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D281H) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (D281H) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (D281H) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D281H) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (D281H) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (D281H) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (D281H) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| PML | PML MUT* (R358C) | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | PML MUT* (R358C) | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | PML MUT* (R358C) | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| TP53 | TP53 MUT (R342*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R342*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R342*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R342*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R342*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R342*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R342*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R342*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R342*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R342*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R342*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R342*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R342*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R342*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R342*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | PIK3CA MUT (N1044K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (N1044K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (N1044K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (N1044K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (N1044K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (N1044K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (N1044K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (N1044K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (N1044K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (N1044K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (N1044K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (N1044K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (N1044K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (N1044K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (E286V) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E286V) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E286V) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E286V) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E286V) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E286V) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E286V) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E286V) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E286V) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E286V) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E286V) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E286V) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E286V) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E286V) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E286V) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (5-UTRSNV), ALK MUT* (intron_variant) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | TP53 MUT (P278R) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (P278R) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (P278R) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (P278R) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (P278R) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (P278R) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (P278R) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278R) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278R) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (P278R) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (P278R) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278R) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (P278R) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (P278R) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (P278R) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y220C) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y220C) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y220C) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| JAK2 | JAK2 MUT* (E1052*) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| TP53 | TP53 MUT (Q331H) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Q331H) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Q331H) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Q331H) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Q331H) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Q331H) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Q331H) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q331H) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q331H) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Q331H) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Q331H) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q331H) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q331H) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Q331H) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q331H) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | PIK3CA MUT (H1047L) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (H1047L) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| BRAF | BRAF MUT* (N148S) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (N148S) | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (N148S) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | BRAF MUT* (N148S) | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| BRAF | BRAF MUT* (intron_variant), BRAF MUT* (S535S) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (intron_variant), BRAF MUT* (S535S) | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (intron_variant), BRAF MUT* (S535S) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | BRAF MUT* (intron_variant), BRAF MUT* (S535S) | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| TP53 | TP53 MUT (E224D) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E224D) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E224D) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E224D) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E224D) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E224D) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E224D) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E224D) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E224D) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E224D) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E224D) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E224D) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E224D) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E224D) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E224D) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| FGFR3 | FGFR3 MUT* (intron_variant) | Different Alteration | FGFR inhibitor | Responsive | BLCA | Case report |
| FGFR3 | FGFR3 MUT* (intron_variant) | Different Alteration | FGFR inhibitor | Responsive | G | Early trials |
| FGFR3 | FGFR3 MUT* (intron_variant) | Different Alteration | FGFR inhibitor | Responsive | NSCLC | Pre-clinical |
| TP53 | TP53 MUT (D259Y) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (D259Y) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (D259Y) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (D259Y) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (D259Y) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (D259Y) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (D259Y) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D259Y) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D259Y) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (D259Y) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (D259Y) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D259Y) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (D259Y) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (D259Y) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (D259Y) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| Variation | Gene | Transcript | Protein Alteration | Consequence | Tumour Driver | Oncogenic Classification |
|---|
Loading...
Drug-Gene Interactions help
Druggable categories in the cohort
No meaningful categories found
Focus the search to a gene of interest:
Loading...
| Gene | Interaction Source | Interaction Types | Drug Claim Primary Name | Drug Name | ChEMBL ID |
|---|---|---|---|---|---|
| PIK3CA | MyCancerGenome | inhibitor | INK-1117 | INK-1117 | CHEMBL3545055 |
| PIK3CA | CKB | MS417 | |||
| PIK3CA | CIViC | RAPAMYCIN (SIROLIMUS) | SIROLIMUS | CHEMBL413 | |
| PIK3CA | CGI | Chemotherapy | |||
| PIK3CA | CKB | Olaparib | OLAPARIB | CHEMBL521686 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | HS-173 | ||
| PIK3CA | CKB | Linsitinib | LINSITINIB | CHEMBL1091644 | |
| PIK3CA | CKB | ZSTK474 | ZSTK-474 | CHEMBL586701 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | AMG319 | AMG-319 | CHEMBL3545048 |
| PIK3CA | MyCancerGenome | inhibitor | BKM120 | BUPARLISIB | CHEMBL2017974 |
| PIK3CA | ClearityFoundationBiomarkers | BYL719 | ALPELISIB | CHEMBL2396661 | |
| PIK3CA | NCI | I3C | INDOLE-3-CARBINOL | CHEMBL155625 | |
| PIK3CA | CKB | GDC-0941 | PICTILISIB | CHEMBL521851 | |
| PIK3CA | CKB | Navitoclax | NAVITOCLAX | CHEMBL443684 | |
| PIK3CA | CIViC | PICTILISIB | PICTILISIB | CHEMBL521851 | |
| PIK3CA | ChemblInteractions | inhibitor | SF-1126 | SF-1126 | CHEMBL2326966 |
| PIK3CA | ClearityFoundationBiomarkers | DS-7423 | DS-7423 | CHEMBL3545248 | |
| PIK3CA | GuideToPharmacologyInteractions | allosteric modulator | PIK-108 | ||
| PIK3CA | CKB | Neratinib | NERATINIB | CHEMBL180022 | |
| PIK3CA | CGI | Cetuximab | CETUXIMAB | CHEMBL1201577 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | AZD8186 | AZD-8186 | CHEMBL3545424 |
| PIK3CA | CKB | DS-7423 | DS-7423 | CHEMBL3545248 | |
| PIK3CA | OncoKB | Copanlisib | COPANLISIB | CHEMBL3218576 | |
| PIK3CA | NCI | SERM | |||
| PIK3CA | CKB | ASN003 | |||
| PIK3CA | CIViC | PP242 | |||
| PIK3CA | CKB | AZD6482 | AZD-6482 | CHEMBL2165191 | |
| PIK3CA | CIViC | BYL719 (ALPELISIB) | |||
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | PX-866 | SONOLISIB | CHEMBL411907 |
| PIK3CA | CKB | AZD5363 | AZD-5363 | CHEMBL2178577 | |
| PIK3CA | CKB | GDC-0980 | APITOLISIB | CHEMBL1922094 | |
| PIK3CA | CKB | Radiotherapy | |||
| PIK3CA | CKB | Palbociclib | PALBOCICLIB | CHEMBL189963 | |
| PIK3CA | CKB | LY2780301 | LY-2780301 | CHEMBL3545134 | |
| PIK3CA | NCI | RAS INHIBITOR | |||
| PIK3CA | OncoKB | AZD5363 | AZD-5363 | CHEMBL2178577 | |
| PIK3CA | NCI | HGF | |||
| PIK3CA | CIViC | EVEROLIMUS | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | CKB | Tamoxifen | TAMOXIFEN | CHEMBL83 | |
| PIK3CA | CKB | Trametinib | TRAMETINIB | CHEMBL2103875 | |
| PIK3CA | NCI | RAPAMYCIN | SIROLIMUS | CHEMBL413 | |
| PIK3CA | CKB | TGX-221 | |||
| PIK3CA | MyCancerGenome | inhibitor | GDC-0032 | TASELISIB | CHEMBL2387080 |
| PIK3CA | ChemblInteractions | inhibitor | PILARALISIB | PILARALISIB (CHEMBL3360203) | CHEMBL3360203 |
| PIK3CA | ChemblInteractions | inhibitor | PWT-33587 | PWT-33587 | CHEMBL3545006 |
| PIK3CA | ChemblInteractions | inhibitor | RECILISIB | RECILISIB | CHEMBL2219421 |
| PIK3CA | CIViC | CETUXIMAB | CETUXIMAB | CHEMBL1201577 | |
| PIK3CA | CIViC | LAPATINIB | LAPATINIB | CHEMBL554 | |
| PIK3CA | CKB | CUDC-907 | CUDC-907 | CHEMBL3545052 | |
| PIK3CA | CKB | VS-5584 | VS-5584 | CHEMBL1079593 | |
| PIK3CA | CKB | Lapatinib | LAPATINIB | CHEMBL554 | |
| PIK3CA | CKB | Selumetinib | SELUMETINIB | CHEMBL1614701 | |
| PIK3CA | CKB | GSK2126458 | OMIPALISIB | CHEMBL1236962 | |
| PIK3CA | NCI | SELECTIVE ESTROGEN RECEPTOR MODULATOR | |||
| PIK3CA | OncoKB | Letrozole | LETROZOLE | CHEMBL1444 | |
| PIK3CA | CKB | GSK1059615 | GSK-1059615 | CHEMBL3544966 | |
| PIK3CA | ChemblInteractions | inhibitor | PA-799 | PA-799 | CHEMBL1684984 |
| PIK3CA | CKB | ARQ092 | ARQ-092 | CHEMBL3545422 | |
| PIK3CA | CKB | BGJ398 | INFIGRATINIB | CHEMBL1852688 | |
| PIK3CA | ChemblInteractions | inhibitor | TASELISIB | TASELISIB | CHEMBL2387080 |
| PIK3CA | MyCancerGenome | inhibitor | XL147 | PILARALISIB (CHEMBL3218575) | CHEMBL3218575 |
| PIK3CA | ChemblInteractions | inhibitor | VS-5584 | VS-5584 | CHEMBL1079593 |
| PIK3CA | OncoKB | MLN0128 | INK-128 | CHEMBL3545056 | |
| PIK3CA | TdgClinicalTrial | RIGOSERTIB | RIGOSERTIB | CHEMBL1241855 | |
| PIK3CA | CKB | Cisplatin | |||
| PIK3CA | ChemblInteractions | inhibitor | COPANLISIB | COPANLISIB | CHEMBL3218576 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PI 3-KG INHIBITOR II | CHEMBL1231533 | CHEMBL1231533 |
| PIK3CA | CIViC | PERIFOSINE | PERIFOSINE | CHEMBL372764 | |
| PIK3CA | ChemblInteractions | inhibitor | PF-04691502 | PF-04691502 | CHEMBL1234354 |
| PIK3CA | ChemblInteractions | inhibitor | SONOLISIB | SONOLISIB | CHEMBL411907 |
| PIK3CA | ChemblInteractions | inhibitor | PKI-179 | PKI-179 | CHEMBL1258517 |
| PIK3CA | MyCancerGenome | inhibitor | GDC-0980 | APITOLISIB | CHEMBL1922094 |
| PIK3CA | CKB | Demcizumab | DEMCIZUMAB | CHEMBL2109384 | |
| PIK3CA | NCI | FLAVOPIRIDOL | ALVOCIDIB | CHEMBL428690 | |
| PIK3CA | NCI | PKC412 | MIDOSTAURIN | CHEMBL608533 | |
| PIK3CA | ChemblInteractions | inhibitor | CUDC-907 | CUDC-907 | CHEMBL3545052 |
| PIK3CA | CKB | P7170 | Panulisib | CHEMBL3545322 | |
| PIK3CA | ClearityFoundationBiomarkers | GSK2126458 | OMIPALISIB | CHEMBL1236962 | |
| PIK3CA | CKB | MLN0128 | INK-128 | CHEMBL3545056 | |
| PIK3CA | CancerCommons | inhibitor | BKM120 | BUPARLISIB | CHEMBL2017974 |
| PIK3CA | OncoKB | Serabelisib | YOHIMBINE | CHEMBL15245 | |
| PIK3CA | ChemblInteractions | inhibitor | INK-1117 | INK-1117 | CHEMBL3545055 |
| PIK3CA | NCI | IL-2 | |||
| PIK3CA | CKB | Bevacizumab | BEVACIZUMAB | CHEMBL1201583 | |
| PIK3CA | MyCancerGenome | inhibitor | GSK2636771 | GSK-2636771 | CHEMBL3188551 |
| PIK3CA | CKB | PKI-179 | PKI-179 | CHEMBL1258517 | |
| PIK3CA | ClearityFoundationBiomarkers | BAY80-6946 | COPANLISIB | CHEMBL3218576 | |
| PIK3CA | CIViC | PALBOCICLIB (PD0332991) | PALBOCICLIB | CHEMBL189963 | |
| PIK3CA | CKB | Idelalisib | IDELALISIB | CHEMBL2216870 | |
| PIK3CA | ChemblInteractions | inhibitor | LY-3023414 | LY-3023414 | CHEMBL3544999 |
| PIK3CA | CIViC | TEMSIROLIMUS | TEMSIROLIMUS | CHEMBL1201182 | |
| PIK3CA | CIViC | AZD5363 | AZD-5363 | CHEMBL2178577 | |
| PIK3CA | NCI | THEAFLAVINS | |||
| PIK3CA | CIViC | IDELALISIB | IDELALISIB | CHEMBL2216870 | |
| PIK3CA | NCI | PTHRP | |||
| PIK3CA | CKB | GSK2334470 | CHEMBL1765740 | CHEMBL1765740 | |
| PIK3CA | CKB | Doxil | |||
| PIK3CA | CIViC | CISPLATIN | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | LY 294002 | LY-294002 | CHEMBL98350 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | ECF309 | ||
| PIK3CA | ClearityFoundationBiomarkers | PF-05212384 | GEDATOLISIB | CHEMBL592445 | |
| PIK3CA | ClearityFoundationBiomarkers | ZSTK474 | ZSTK-474 | CHEMBL586701 | |
| PIK3CA | NCI | RALOXIFENE | RALOXIFENE | CHEMBL81 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PIK-75 | ||
| PIK3CA | ChemblInteractions | inhibitor | DACTOLISIB | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | CKB | Ponatinib | PONATINIB | CHEMBL1171837 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | CH5132799 | PA-799 | CHEMBL1684984 |
| PIK3CA | CIViC | ANTI-EGFR MONOCLONAL ANTIBODY | |||
| PIK3CA | ClearityFoundationBiomarkers | TEMSIROLIMUS | TEMSIROLIMUS | CHEMBL1201182 | |
| PIK3CA | CKB | BAY1125976 | BAY-1125976 | CHEMBL3545049 | |
| PIK3CA | CKB | Sirolimus | SIROLIMUS | CHEMBL413 | |
| PIK3CA | CKB | GSK2141795 | UPROSERTIB | CHEMBL3137336 | |
| PIK3CA | MyCancerGenome | inhibitor | PI-103 | PI-103 | CHEMBL573339 |
| PIK3CA | CKB | Alpelisib | ALPELISIB | CHEMBL2396661 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | APITOLISIB | APITOLISIB | CHEMBL1922094 |
| PIK3CA | ChemblInteractions | inhibitor | RG-7666 | RG-7666 | CHEMBL3545324 |
| PIK3CA | CKB | Doxorubicin | DOXORUBICIN | CHEMBL53463 | |
| PIK3CA | CKB | LY294002 | LY-294002 | CHEMBL98350 | |
| PIK3CA | CKB | AT-7867 | CHEMBL428462 | CHEMBL428462 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | BGT-226 | ||
| PIK3CA | NCI | SULINDAC | SULINDAC | CHEMBL15770 | |
| PIK3CA | NCI | CAMPTOTHECIN | CAMPTOTHECIN | CHEMBL65 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | TASELISIB | TASELISIB | CHEMBL2387080 |
| PIK3CA | CKB | WEHI-539 | |||
| PIK3CA | CKB | GDC-0032 | TASELISIB | CHEMBL2387080 | |
| PIK3CA | CKB | Fluorouracil | FLUOROURACIL | CHEMBL185 | |
| PIK3CA | MyCancerGenome | inhibitor | PKI-587 | GEDATOLISIB | CHEMBL592445 |
| PIK3CA | ChemblInteractions | inhibitor | ZSTK-474 | ZSTK-474 | CHEMBL586701 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | BUPARLISIB | BUPARLISIB | CHEMBL2017974 |
| PIK3CA | CancerCommons | inhibitor | BEZ235 | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | CKB | YM-024 | |||
| PIK3CA | CKB | PKI-402 | CHEMBL589258 | CHEMBL589258 | |
| PIK3CA | CIViC | PI3K INHIBITOR | |||
| PIK3CA | ChemblInteractions | inhibitor | BGT-226 | BGT-226 (CHEMBL3545096) | CHEMBL3545096 |
| PIK3CA | CKB | Vistusertib | BENZONATATE | CHEMBL1374379 | |
| PIK3CA | CKB | Paclitaxel | PACLITAXEL | CHEMBL428647 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | LENIOLISIB | ||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PQR309 | ||
| PIK3CA | TdgClinicalTrial | SF1126 | SF-1126 | CHEMBL2326966 | |
| PIK3CA | CKB | FOLFOX | |||
| PIK3CA | CKB | rigosertib | RIGOSERTIB | CHEMBL1241855 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PICTILISIB | PICTILISIB | CHEMBL521851 |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | BYL719 | ALPELISIB | CHEMBL2396661 |
| PIK3CA | NCI | STZ | STREPTOZOTOCIN | CHEMBL1651906 | |
| PIK3CA | NCI | HERBIMYCIN A | HERBIMYCIN | CHEMBL479533 | |
| PIK3CA | CKB | Sapanisertib | INK-128 | CHEMBL3545056 | |
| PIK3CA | CKB | A-443654 | A-443654 | CHEMBL379300 | |
| PIK3CA | CKB | AZD8055 | AZD-8055 | CHEMBL1801204 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | AZD8835 | CANDICIDIN | CHEMBL1200647 |
| PIK3CA | MyCancerGenome | inhibitor | XL-765 | VOXTALISIB | CHEMBL3545366 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | OMIPALISIB | OMIPALISIB | CHEMBL1236962 |
| PIK3CA | OncoKB | Taselisib | TASELISIB | CHEMBL2387080 | |
| PIK3CA | OncoKB | Ribociclib | Ribociclib | CHEMBL3545110 | |
| PIK3CA | ChemblInteractions | inhibitor | GSK-1059615 | GSK-1059615 | CHEMBL3544966 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | AZD6482 | AZD-6482 | CHEMBL2165191 |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | PKI-587 | GEDATOLISIB | CHEMBL592445 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | COMPOUND 28 [PMID: 24387221] | ||
| PIK3CA | CKB | Pertuzumab | PERTUZUMAB | CHEMBL2007641 | |
| PIK3CA | MyCancerGenome | inhibitor | SF1126 | SF-1126 | CHEMBL2326966 |
| PIK3CA | CKB | Fulvestrant | FULVESTRANT | CHEMBL1358 | |
| PIK3CA | CKB | OSI-027 | OSI-027 | CHEMBL3120215 | |
| PIK3CA | ChemblInteractions | inhibitor | APITOLISIB | APITOLISIB | CHEMBL1922094 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PI-103 | PI-103 | CHEMBL573339 |
| PIK3CA | ChemblInteractions | inhibitor | VOXTALISIB | VOXTALISIB | CHEMBL3545366 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | ZSTK474 | ZSTK-474 | CHEMBL586701 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | TG-100-115 | TG100-115 | CHEMBL230011 |
| PIK3CA | CKB | PI-103 | PI-103 | CHEMBL573339 | |
| PIK3CA | MyCancerGenome | inhibitor | PWT33597 | ||
| PIK3CA | NCI | PACLITAXEL | PACLITAXEL | CHEMBL428647 | |
| PIK3CA | CKB | U0126 | U-0126 | CHEMBL100473 | |
| PIK3CA | CIViC | RADIATION | |||
| PIK3CA | CKB | Lucitanib | LUCITANIB | CHEMBL2220486 | |
| PIK3CA | OncoKB | Trastuzumab | TRASTUZUMAB | CHEMBL1201585 | |
| PIK3CA | CKB | Torin 1 | TORIN1 | CHEMBL1256459 | |
| PIK3CA | CKB | Carboxyamidotriazole Orotate | |||
| PIK3CA | CKB | ARQ 751 | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | GEDATOLISIB | GEDATOLISIB | CHEMBL592445 |
| PIK3CA | CKB | AZD8835 | CANDICIDIN | CHEMBL1200647 | |
| PIK3CA | CKB | 5-FU | FLUOROURACIL | CHEMBL185 | |
| PIK3CA | ClearityFoundationBiomarkers | XL-147 | |||
| PIK3CA | NCI | RESVERATROL | RESVERATROL | CHEMBL165 | |
| PIK3CA | CKB | Letrozole | LETROZOLE | CHEMBL1444 | |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | GSK2126458 | OMIPALISIB | CHEMBL1236962 |
| PIK3CA | CKB | SAR245409 | VOXTALISIB | CHEMBL3545366 | |
| PIK3CA | CKB | ABT-263 | NAVITOCLAX | CHEMBL443684 | |
| PIK3CA | CKB | Cetuximab | CETUXIMAB | CHEMBL1201577 | |
| PIK3CA | MyCancerGenome | inhibitor | BGJ398 | ||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PILARALISIB | PILARALISIB (CHEMBL3360203) | CHEMBL3360203 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | VS-5584 | VS-5584 | CHEMBL1079593 |
| PIK3CA | CancerCommons | inhibitor | PX-866 | SONOLISIB | CHEMBL411907 |
| PIK3CA | CKB | NVP-AEW541 | AEW-541 | CHEMBL551064 | |
| PIK3CA | CIViC | CH5132799 | PA-799 | CHEMBL1684984 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | CUDC-907 | CUDC-907 | CHEMBL3545052 |
| PIK3CA | CKB | BKM120 | BUPARLISIB | CHEMBL2017974 | |
| PIK3CA | OncoKB | Everolimus | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | CIViC | BEZ235 (NVP-BEZ235, DACTOLISIB) | DACTOLISIB | CHEMBL1879463 | |
| PIK3CA | ChemblInteractions | inhibitor | DS-7423 | DS-7423 | CHEMBL3545248 |
| PIK3CA | CKB | CH5132799 | PA-799 | CHEMBL1684984 | |
| PIK3CA | CKB | Regorafenib | REGORAFENIB | CHEMBL1946170 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | SERABELISIB | YOHIMBINE | CHEMBL15245 |
| PIK3CA | CGI | Everolimus | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PP121 | CHEMBL1081312 | CHEMBL1081312 |
| PIK3CA | CKB | Temsirolimus | TEMSIROLIMUS | CHEMBL1201182 | |
| PIK3CA | CKB | A-1210477 | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | IDELALISIB | IDELALISIB | CHEMBL2216870 |
| PIK3CA | CKB | MLN1117 | INK-1117 | CHEMBL3545055 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | KU-0060648 | CHEMBL1086377 | CHEMBL1086377 |
| PIK3CA | NCI | DHEA | PRASTERONE | CHEMBL90593 | |
| PIK3CA | CKB | Dabrafenib | DABRAFENIB | CHEMBL2028663 | |
| PIK3CA | NCI | UROKINASE-TYPE PLASMINOGEN ACTIVATOR | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | COMPOUND 11J [PMID: 23021994] | ||
| PIK3CA | ChemblInteractions | inhibitor | OMIPALISIB | OMIPALISIB | CHEMBL1236962 |
| PIK3CA | CKB | Ridaforolimus | RIDAFOROLIMUS | CHEMBL2103839 | |
| PIK3CA | MyCancerGenome | inhibitor | PF-4691502 | PF-04691502 | CHEMBL1234354 |
| PIK3CA | CKB | Copanlisib | COPANLISIB | CHEMBL3218576 | |
| PIK3CA | NCI | BCG | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PF-04691502 | PF-04691502 | CHEMBL1234354 |
| PIK3CA | OncoKB | LJM716 | |||
| PIK3CA | OncoKB | Olaparib | OLAPARIB | CHEMBL521686 | |
| PIK3CA | NCI | 17-AAG | CHEMBL126955 | CHEMBL126955 | |
| PIK3CA | NCI | NSAID | |||
| PIK3CA | MyCancerGenome | inhibitor | GDC-0941 | PICTILISIB | CHEMBL521851 |
| PIK3CA | ChemblInteractions | inhibitor | AZD-6482 | AZD-6482 | CHEMBL2165191 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | WORTMANNIN | WORTMANNIN | CHEMBL428496 |
| PIK3CA | CKB | GS-9820 | Acalisib | CHEMBL3545397 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | NEMIRALISIB | ||
| PIK3CA | CKB | Torkinib | |||
| PIK3CA | CKB | PD-0325901 | PD-0325901 | CHEMBL507361 | |
| PIK3CA | CKB | Gemcitabine | GEMCITABINE | CHEMBL888 | |
| PIK3CA | CKB | Deguelin | DEGUELIN | CHEMBL393417 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | INK-128 | INK-128 | CHEMBL3545056 |
| PIK3CA | CKB | Dasatinib | DASATINIB | CHEMBL1421 | |
| PIK3CA | CancerCommons | inhibitor | BAY80-6946 | COPANLISIB | CHEMBL3218576 |
| PIK3CA | NCI | TRAIL | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PI 3-KG INHIBITOR | CHEMBL568150 | CHEMBL568150 |
| PIK3CA | NCI | GM-CSF | REGRAMOSTIM | CHEMBL2107881 | |
| PIK3CA | MyCancerGenome | inhibitor | BAY80-6946 | COPANLISIB | CHEMBL3218576 |
| PIK3CA | CKB | CCT128930 | CHEMBL263664 | CHEMBL263664 | |
| PIK3CA | TdgClinicalTrial | PWT33597 | |||
| PIK3CA | NCI | ZINC SULFATE | ZINC SULFATE | CHEMBL1200929 | |
| PIK3CA | CKB | trastuzumab emtansine | TRASTUZUMAB EMTANSINE | CHEMBL1743082 | |
| PIK3CA | CKB | A66 | PHENMETRAZINE | CHEMBL1201208 | |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | DACTOLISIB | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | OncoKB | Fulvestrant | FULVESTRANT | CHEMBL1358 | |
| PIK3CA | MyCancerGenome | inhibitor | PX-866 | SONOLISIB | CHEMBL411907 |
| PIK3CA | MyCancerGenome | inhibitor | SOPHORETIN | QUERCETIN | CHEMBL50 |
| PIK3CA | CKB | BAY1082439 | BAY-1082439 | CHEMBL3545245 | |
| PIK3CA | CIViC | TRASTUZUMAB | TRASTUZUMAB | CHEMBL1201585 | |
| PIK3CA | NCI | CARBOPLATIN | CARBOPLATIN | CHEMBL1351 | |
| PIK3CA | NCI | ANTIANGIOGENIC | |||
| PIK3CA | MyCancerGenome | inhibitor | BEZ235 | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | CKB | PF-05212384 | GEDATOLISIB | CHEMBL592445 | |
| PIK3CA | CKB | WYE-125132 | |||
| PIK3CA | OncoKB | GDC-0077 | PHENMETRAZINE | CHEMBL1201208 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | ALPELISIB | ALPELISIB | CHEMBL2396661 |
| PIK3CA | CIViC | CABOZANTINIB | CABOZANTINIB | CHEMBL2105717 | |
| PIK3CA | NCI | VINCRISTINE | VINCRISTINE | CHEMBL90555 | |
| PIK3CA | NCI | DOXORUBICIN | DOXORUBICIN | CHEMBL53463 | |
| PIK3CA | CKB | BEZ235 | DACTOLISIB | CHEMBL1879463 | |
| PIK3CA | ChemblInteractions | inhibitor | BAY-1082439 | BAY-1082439 | CHEMBL3545245 |
| PIK3CA | CKB | Afuresertib | AFURESERTIB | CHEMBL2219422 | |
| PIK3CA | CancerCommons | inhibitor | BYL719 | ALPELISIB | CHEMBL2396661 |
| PIK3CA | CKB | Floxuridine | FLOXURIDINE | CHEMBL917 | |
| PIK3CA | CancerCommons | inhibitor | XL765 | VOXTALISIB | CHEMBL3545366 |
| PIK3CA | ClearityFoundationBiomarkers | EVEROLIMUS | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | NCI | RETINOID | ETRETINATE | CHEMBL464 | |
| PIK3CA | CKB | DHM25 | |||
| PIK3CA | CKB | Gedatolisib | GEDATOLISIB | CHEMBL592445 | |
| PIK3CA | CKB | PWT33597 | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | LY3023414 | LY-3023414 | CHEMBL3544999 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | COMPOUND 82 [PMID: 21332118] | ||
| PIK3CA | CKB | Camptothecin | CAMPTOTHECIN | CHEMBL65 | |
| PIK3CA | ChemblInteractions | inhibitor | WX-037 | WX-037 | CHEMBL3545385 |
| PIK3CA | CKB | Venetoclax | VENETOCLAX | CHEMBL3137309 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | QUINOSTATIN | ||
| PIK3CA | NCI | TYROSINE KINASE INHIBITORS | |||
| PIK3CA | ChemblInteractions | inhibitor | Puquitinib | Puquitinib | CHEMBL3545088 |
| PIK3CA | ChemblInteractions | inhibitor | PWT-33579 | PWT-33579 | CHEMBL3545323 |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | BUPARLISIB HYDROCHLORIDE | BUPARLISIB HYDROCHLORIDE | CHEMBL2364604 |
| PIK3CA | CKB | ABT-737 | CHEMBL376408 | CHEMBL376408 | |
| PIK3CA | CIViC | PANITUMUMAB | PANITUMUMAB | CHEMBL1201827 | |
| PIK3CA | ChemblInteractions | inhibitor | GEDATOLISIB | GEDATOLISIB | CHEMBL592445 |
| PIK3CA | CKB | XL147 | PILARALISIB (CHEMBL3218575) | CHEMBL3218575 | |
| PIK3CA | CIViC | MK-2206 | MK-2206 | CHEMBL1079175 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | IPI549 | OXAZEPAM | CHEMBL568 |
| PIK3CA | CKB | BYL719 | ALPELISIB | CHEMBL2396661 | |
| PIK3CA | ChemblInteractions | inhibitor | BUPARLISIB | BUPARLISIB | CHEMBL2017974 |
| PIK3CA | CKB | MK2206 | MK-2206 | CHEMBL1079175 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | DACTOLISIB | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | ChemblInteractions | inhibitor | Panulisib | Panulisib | CHEMBL3545322 |
| PIK3CA | CKB | PD98509 | |||
| PIK3CA | CancerCommons | inhibitor | SAR260301 | SAR-260301 | CHEMBL3545008 |
| PIK3CA | CKB | Metformin | METFORMIN | CHEMBL1431 | |
| PIK3CA | CKB | Vemurafenib | VEMURAFENIB | CHEMBL1229517 | |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | BAY80-6946 | COPANLISIB | CHEMBL3218576 |
| PIK3CA | NCI | SURAMIN | SURAMIN | CHEMBL265502 | |
| PIK3CA | CKB | Capecitabine | CAPECITABINE | CHEMBL1773 | |
| PIK3CA | ClearityFoundationBiomarkers | XL765 | VOXTALISIB | CHEMBL3545366 | |
| PIK3CA | CKB | Everolimus | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | ClearityFoundationBiomarkers | NVP-BEZ235 | DACTOLISIB | CHEMBL1879463 | |
| PIK3CA | CKB | Pimasertib | PIMASERTIB | CHEMBL2107832 | |
| PIK3CA | MyCancerGenome | inhibitor | BYL719 | ALPELISIB | CHEMBL2396661 |
| PIK3CA | CKB | PF-04691502 | PF-04691502 | CHEMBL1234354 | |
| PIK3CA | CIViC | TASELISIB (GDC-0032) | |||
| PIK3CA | NCI | MILTEFOSINE | MILTEFOSINE | CHEMBL125 | |
| PIK3CA | NCI | QUERCETIN | QUERCETIN | CHEMBL50 | |
| PIK3CA | CGI | Trastuzumab | TRASTUZUMAB | CHEMBL1201585 | |
| PIK3CA | TdgClinicalTrial | XL765 | VOXTALISIB | CHEMBL3545366 | |
| PIK3CA | CKB | AT13148 | AT-13148 | CHEMBL3544960 | |
| PIK3CA | ChemblInteractions | inhibitor | ALPELISIB | ALPELISIB | CHEMBL2396661 |
| PIK3CA | CKB | Irinotecan | IRINOTECAN | CHEMBL481 | |
| PIK3CA | CKB | CGM097 | |||
| PIK3CA | CKB | MSC2363318A | MSC-2363318A | CHEMBL3545003 | |
| PIK3CA | CKB | PW12 | |||
| PIK3CA | NCI | 17-ALLYL-AMINOGELDANAMYCIN | CHEMBL126955 | CHEMBL126955 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | GDC-0077 | PHENMETRAZINE | CHEMBL1201208 |
| PIK3CA | CKB | CC-223 | CC-223 | CHEMBL3545151 | |
| PIK3CA | CKB | cobimetinib | COBIMETINIB | CHEMBL2146883 | |
| PIK3CA | NCI | CPT-11 | IRINOTECAN | CHEMBL481 | |
| PIK3CA | OncoKB | Buparlisib | BUPARLISIB | CHEMBL2017974 | |
| PIK3CA | NCI | IL-11 | |||
| PIK3CA | CKB | Trastuzumab | TRASTUZUMAB | CHEMBL1201585 | |
| PIK3CA | OncoKB | ASN003 | |||
| PIK3CA | CKB | Sorafenib | SORAFENIB | CHEMBL1336 | |
| PIK3CA | CKB | PF-4989216 | |||
| PIK3CA | CKB | TAK-733 | TAK-733 | CHEMBL1615025 | |
| PIK3CA | CKB | LY3023414 | LY-3023414 | CHEMBL3544999 | |
| PIK3CA | CKB | PX-866 | SONOLISIB | CHEMBL411907 | |
| PIK3CA | CKB | Bortezomib | BORTEZOMIB | CHEMBL325041 | |
| PIK3CA | CKB | Carboplatin | CARBOPLATIN | CHEMBL1351 | |
| PIK3CA | ChemblInteractions | inhibitor | PICTILISIB | PICTILISIB | CHEMBL521851 |
| PIK3CA | OncoKB | Alpelisib | ALPELISIB | CHEMBL2396661 | |
| PIK3CA | CKB | Ipatasertib | IPATASERTIB | CHEMBL2177390 | |
| PIK3CA | ClearityFoundationBiomarkers | PF-04691502 | PF-04691502 | CHEMBL1234354 | |
| PIK3CA | CKB | Topotecan | TOPOTECAN | CHEMBL84 | |
| PIK3CA | CIViC | RIBOCICLIB | Ribociclib | CHEMBL3545110 | |
| PIK3CA | ChemblInteractions | inhibitor | MLN-1117 | MLN-1117 | CHEMBL3545379 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | DUVELISIB | DUVELISIB | CHEMBL3039502 |
Phenotype
Protein
Drug
Loading...
There are patients available from the BCN Biobank that match the selected/a subset of the criteria. Explore the data available for these patients using our Cohort Browser.
Researchers can request samples from BCNB website to support their research activities.
*Based on your filtering criteria you can view the number of available patients and associated samples in BCNBIn order to apply for samples, please use the BCNB Request System to submit an Expression of interest (EOI) form.
If you require further details please contact us at tissue.bank@breastcancernow.org
| Patient ID | Age at Diagnosis | Sex | Family History | Family History Relative | Tumour Stage | Survival Status | Survival Time |
|---|---|---|---|---|---|---|---|
| DO228328 | 82 | female | NA | no | T2N0M0 | alive | 0.4 |
| DO227934 | 46 | female | yes | yes | T2N0M0 | alive | 0.53 |
| DO228317 | 57 | female | NA | no | T0N0M0 | alive | 0.59 |
| DO227949 | 57 | female | yes | yes | T2N1M0 | alive | 0.68 |
| DO227948 | 76 | female | yes | yes | T0N0M0 | alive | 0.98 |
| DO228306 | 66 | female | NA | no | T2N0M0 | alive | 0.98 |
| DO228324 | 48 | female | NA | no | T1N0M0 | alive | 1.0 |
| DO227945 | 69 | female | NA | no | T1N0M0 | alive | 1.49 |
| DO227942 | 56 | female | NA | no | T2N0M0 | alive | 1.51 |
| DO227943 | 58 | female | NA | no | T0N0M0 | alive | 1.52 |
| DO227946 | 62 | female | yes | yes | T2N0M0 | alive | 1.57 |
| DO227941 | 32 | female | yes | yes | T1N0M0 | alive | 1.68 |
| DO227947 | 59 | female | NA | no | T3N1M0 | alive | 1.76 |
| DO228345 | 54 | female | yes | yes | NA | alive | 2.12 |
| DO227940 | 67 | female | NA | no | T2N1M0 | alive | 2.22 |
| DO227939 | 76 | female | yes | yes | T3N1M0 | alive | 2.22 |
| DO227578 | 59 | female | NA | no | T1N0M0 | alive | 2.23 |
| DO228331 | 62 | female | yes | yes | T1N1M0 | alive | 2.38 |
| DO227651 | 62 | female | yes | yes | T2N0M0 | alive | 2.46 |
| DO227892 | 63 | female | yes | yes | T2N1M0 | alive | 2.52 |
| DO227803 | 56 | female | yes | yes | T2N1M0 | alive | 2.6 |
| DO227918 | 70 | female | NA | no | T2N0M0 | alive | 2.69 |
| DO227935 | 52 | female | yes | yes | T2N2M0 | alive | 2.78 |
| DO227938 | 62 | female | NA | no | T2N0M0 | alive | 2.81 |
| DO227909 | 66 | female | NA | no | T2N0M0 | alive | 3.01 |
| DO227860 | 31 | female | NA | no | T3N1M0 | alive | 3.21 |
| DO227928 | 36 | female | NA | no | T2N2M0 | alive | 3.35 |
| DO227503 | 56 | female | NA | no | T2N1M0 | alive | 3.57 |
| DO227871 | 69 | female | NA | no | T2N1M0 | alive | 3.6 |
| DO227916 | 56 | female | yes | no | NA | alive | 3.67 |
| DO227930 | 41 | female | NA | no | T2N1M0 | alive | 3.67 |
| DO227857 | 45 | female | NA | no | T2N0M0 | alive | 3.71 |
| DO227936 | 42 | female | NA | no | T2N1M0 | alive | 3.74 |
| DO227820 | 67 | female | yes | yes | T2N0M0 | alive | 3.83 |
| DO227809 | 60 | female | NA | no | T2N1M0 | alive | 4.05 |
| DO227851 | 51 | female | NA | no | T1N0M0 | alive | 4.07 |
| DO227836 | 56 | female | yes | yes | T2N0M0 | alive | 4.1 |
| DO227921 | 64 | female | yes | yes | T2N0M0 | alive | 4.17 |
| DO227903 | 78 | female | NA | no | T2N0M0 | alive | 4.17 |
| DO227886 | 61 | female | yes | yes | T2N0M0 | alive | 4.25 |
| DO227812 | 44 | female | yes | yes | T2N0M0 | alive | 4.36 |
| DO227719 | 37 | female | NA | no | T1N0M0 | alive | 4.39 |
| DO227838 | 47 | female | yes | yes | T2N1M0 | alive | 4.49 |
| DO227830 | 55 | female | yes | yes | T1N0M0 | alive | 4.5 |
| DO227944 | 62 | female | yes | yes | T2N2M0 | alive | 4.54 |
| DO227878 | 49 | female | NA | no | T2N1M0 | alive | 4.56 |
| DO227899 | 70 | female | NA | no | T2N1M0 | alive | 4.57 |
| DO227773 | 39 | female | yes | yes | T2N0M0 | alive | 4.59 |
| DO227678 | 63 | female | NA | no | T2N1M0 | alive | 4.59 |
| DO227843 | 40 | female | NA | no | T2N1M0 | alive | 4.6 |
| DO227865 | 47 | female | NA | no | T1N0M0 | alive | 4.6 |
| DO227535 | 70 | female | NA | no | T1N0M0 | alive | 4.65 |
| DO227854 | 55 | female | NA | no | T3N1M0 | alive | 4.65 |
| DO227787 | 71 | female | yes | yes | T1N1M0 | alive | 4.66 |
| DO227924 | 39 | female | yes | no | T2N1M0 | alive | 4.66 |
| DO227749 | 46 | female | NA | no | T4N2M0 | alive | 4.81 |
| DO227663 | 55 | female | NA | no | T2N3M0 | alive | 4.83 |
| DO227632 | 38 | female | NA | no | T1N1M0 | alive | 4.86 |
| DO227566 | 54 | female | NA | no | T1N0M0 | alive | 4.87 |
| DO227815 | 63 | female | yes | yes | T2N1M0 | alive | 4.91 |
| DO227494 | 62 | female | yes | yes | T1N1M0 | alive | 4.97 |
| DO227510 | 64 | female | yes | yes | T2N0M0 | alive | 4.97 |
| DO227683 | 76 | female | yes | no | T1N3M0 | alive | 4.97 |
| DO227806 | 34 | female | yes | yes | T1N2M0 | alive | 4.98 |
| DO227937 | 61 | female | yes | yes | T1N0M0 | alive | 4.98 |
| DO227784 | 65 | female | NA | no | T2N1M0 | alive | 4.99 |
| DO227507 | 51 | female | yes | yes | T1N0M0 | alive | 4.99 |
| DO227593 | 48 | female | NA | no | T2N0M0 | alive | 4.99 |
| DO227561 | 44 | female | NA | no | T1N0M0 | alive | 5.01 |
| DO227645 | 54 | female | NA | no | T1N0M0 | alive | 5.02 |
| DO227666 | 34 | female | yes | yes | T3N1M0 | alive | 5.02 |
| DO227541 | 34 | female | yes | no | T1N0M0 | alive | 5.02 |
| DO227673 | 67 | female | yes | yes | T1N3M0 | alive | 5.04 |
| DO227817 | 52 | female | yes | yes | T1N1M0 | alive | 5.07 |
| DO227764 | 39 | female | yes | no | NA | alive | 5.11 |
| DO227776 | 40 | female | yes | no | T2N1M0 | alive | 5.11 |
| DO227473 | 48 | female | yes | yes | T2N2M0 | alive | 5.11 |
| DO227795 | 38 | female | NA | no | T2N0M0 | alive | 5.11 |
| DO227487 | 56 | female | yes | yes | T2N0M0 | alive | 5.13 |
| DO227618 | 59 | female | NA | no | T1N1M0 | alive | 5.13 |
| DO227932 | 69 | female | NA | no | T2N1M0 | alive | 5.16 |
| DO227521 | 45 | female | NA | no | T2N0M0 | alive | 5.17 |
| DO227846 | 52 | female | yes | no | T2N0M0 | alive | 5.18 |
| DO227862 | 59 | female | yes | no | T2N1M0 | alive | 5.19 |
| DO227912 | 72 | female | NA | no | T2N2M0 | alive | 5.23 |
| DO227827 | 73 | female | NA | no | T1N0M0 | alive | 5.25 |
| DO227475 | 75 | female | NA | no | T2N3M0 | alive | 5.27 |
| DO227517 | 32 | female | NA | no | T2N1M0 | alive | 5.34 |
| DO227483 | 52 | female | yes | yes | T2N0M0 | alive | 5.37 |
| DO227629 | 50 | female | yes | yes | T2N1M0 | alive | 5.41 |
| DO227698 | 47 | female | yes | yes | T1N0M0 | alive | 5.42 |
| DO227480 | 31 | female | yes | no | T1N0M0 | alive | 5.46 |
| DO227490 | 71 | female | yes | yes | T1N1M0 | alive | 5.49 |
| DO227529 | 56 | female | yes | yes | T2N2M0 | alive | 5.52 |
| DO227478 | 55 | female | yes | no | T2N1M0 | alive | 5.59 |
| DO227738 | 43 | female | NA | no | T1N0M0 | alive | 5.65 |
| DO227881 | 58 | female | NA | no | T1N1M0 | alive | 5.66 |
| DO227470 | 55 | female | yes | no | T1N0M0 | alive | 5.73 |
| DO227754 | 56 | female | NA | no | T1N0M0 | alive | 6.12 |
| DO227730 | 45 | female | yes | no | T2N0M0 | alive | 8.19 |
| DO227950 | 58 | female | yes | yes | T1N0M0 | alive | NA |
| DO228314 | 46 | female | yes | yes | NA | alive | NA |
| DO228352 | 32 | female | NA | no | T2N2M0 | alive | NA |
| DO227790 | 41 | female | yes | yes | T2N3M0 | deceased | 2.77 |
| DO227874 | 49 | female | yes | yes | T1N2M0 | deceased | 4.54 |
| DO227701 | 86 | female | NA | no | T3N1M0 | deceased | 4.96 |
| DO227532 | 63 | female | NA | no | T2N2M0 | deceased | 5.73 |